Navigation Links
Hormone linked to high blood pressure and blood vessel disease in African-Americans
Date:2/17/2009

Researchers at The Medical College of Wisconsin in Milwaukee have linked higher levels of the hormone aldosterone to high blood pressure and blood vessel disease in African Americans. Aldosterone is secreted by the adrenal glands and causes salt retention by the kidneys.

The study appeared in the December 18, 2008, American Journal of Hypertension.

"The prevalence of high blood pressure, or hypertension, in African Americans is among the highest in the world," says lead researcher Theodore Kotchen, M.D., professor of medicine and associate dean for clinical research.

"Previously, we found relatively high aldosterone levels in African Americans with high blood pressure," he said. "In this study we have found that aldosterone may not only contribute to high blood pressure but also to related changes in blood vessel function in the kidneys and extremities."

The researchers compared 24-hour blood pressures, heart output, blood vessel stiffness, kidney blood flow, and aldosterone levels in 224 African Americans with high blood pressure, with those of 217 African Americans with normal blood pressure.

They found that those with high blood pressure had higher levels of aldosterone. Their heart output was lower, extremity blood vessel stiffness was greater, kidney blood flow was lower, and kidney resistance to blood flow was higher than those with normal blood pressure.

Most importantly, the blood pressure levels, blood vessel flexibility, and kidney blood flow in those with high blood pressure were all directly correlated with their aldosterone levels.

"These observations suggest that aldosterone contributes to high blood pressure and its related heart, kidney, and blood vessel disease in African Americans," says Dr. Kotchen.


'/>"/>

Contact: Toranj Marphetia
toranj@mcw.edu
414-456-4700
Medical College of Wisconsin
Source:Eurekalert

Page: 1

Related medicine news :

1. Findings raise new questions about evolution of hormones in mammals
2. Male Hormone Replacement Therapy Optimism for 2009
3. Female Hormones Deter Salt-Sensitive Hypertension
4. 2 Years of Hormone Use May Be Safe
5. Growth hormone treatment after weight loss surgery prevents loss of muscle mass
6. Study identifies potential safe period for hormone replacement use
7. The Truth About Bio-identical Hormone Therapy
8. Tweaking Hormones Might Ease Chronic Stress
9. Hormone-Boosting Drug May Help Treat Frailty
10. AstraZenecas Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
11. Newly Released Book by Retired Scientist Links Self-Control of Hormones to Perfecting One's Life

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...cco has been the life-long focus of his research a...Lombardi Comprehensive Cancer Center at Georgetown...edit a special-edition of Cancer Epidemiology, Bi...research practices in tobacco science from researc...BP , a journal of the American Association for Can...
(Date:12/2/2009)... Reportlinker.com announces that a ...alogue: ,, Renal Disease Treatments: Products ...p0166824/Renal-Disease-Treatments-Products-and-The...n products and services, providing data for 2008 a...ket and compound annual growth rates (CAGRs) from ...
(Date:12/2/2009)... Reportlinker.com announces that a ...alogue: ,, Antibiotic Resistance and Antibioti...reportlinker.com/p0166825/Antibiotic-Resistance-an..., Provide an in-depth review of the global market...logies ,, Offer an analysis of antibiotics resi...
(Date:12/2/2009)...d cases, study finds , , WEDNESDAY, Dec....rvival rates for advanced lung cancer patients in ...udy has found. , Researchers analyzed data on m...on-small cell lung cancer (NSCLC) between 1990 and...ional Cancer Institute,s Surveillance, Epidemiolog...
(Date:12/2/2009)...etabolic syndrome, study finds , , WEDNE...n,t enough to keep overweight college football pla...tion that can lead to heart disease, a new study s...ion I colleges and found that two-thirds were obes...group of conditions that raise the risk for heart ...
Breaking Medicine News(10 mins):Health News:Lombardi's Shields leads special journal focused on tobacco research 2Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 2Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 3Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 4Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 5Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 6Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 7Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 8Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 9Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 10Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 2Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 3Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 4Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 5Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 6Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 7Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 8Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 9Health News:Gains Made in Lung Cancer Survival 2Health News:Oversized College Football Players May Face Heart Risks 2
...revent liver failure in thousands of people with H...dy published tomorrow (1 August) in the Journal o...at warfarin reduces the scarring on the liver caus...llowing the new findings in mouse models, the Impe...
... saves over $2 million in conducting the company,s...IV and safety registry - with Clinipace,s TEMPO re...h Triangle Park, NC (PRWEB) July 31, 2008 -- Clini...rect costs associated with conducing two research ...
...are Health,Systems, Inc. (Amex: ADK ), an Ohio ba...ny, today announced the refinancing of one of its ...ld, LLC, is a 50-bed single story nursing home,fac...tchen, laundry, activity and therapy rooms, a new ...
...an Association,of PPOs (AAPPO) today announced the...utives on strategies to improve the value of clini...g Value Initiative will inform AAPPO,members and p..., AAPPO President and CEO Karen Greenrose, commen...
...rtner decreases the risk of developing Alzheimer,s...study by Krister Hkansson, researcher in psycholog...den. The results were presented for the first time... in this field, and the results are astounding. Th...
...l and media,outreach efforts by The Soap and Deter...m ) on the health benefits of hand hygiene have be...a Award of Excellence., The honor is given annual... training, business and social,innovation, knowled...
Other Medicine News:Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 3Health News:On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace 2Health News:On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace 3Health News:On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace 4Health News:AdCare Health Systems, Inc. Announces the Refinancing of a Nursing Home in Ohio 2Health News:AAPPO Launches Short Course Conference Call Series on Value-added Strategies for PPOs 2Health News:Living with a partner reduces risk of Alzheimer's 2Health News:SDA Hygiene Outreach Efforts Honored with Award of Excellence 2Health News:SDA Hygiene Outreach Efforts Honored with Award of Excellence 3
(Date:12/2/2009)... , PALO ALTO, Calif., Dec. 2 /PRNewswire-First...hat on November 25, 2009, Varian, Inc. filed with ...nual Report on Form 10-K for the fiscal year ended...sed through the Company,s web site at www.varianin...," and then on "10-K" in the table shown. Stockho...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Report...port is available in its catalogue: ,, Hemoglo...http://www.reportlinker.com/p0164230/Hemoglobin-A1...e seriousness of affliction and the need for effec...rgence of a significant market for monitoring the ...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Report...port is available in its catalogue: ,, Global.../www.reportlinker.com/p0166826/Global-Markets-for-...epth analysis of the global market for medications...ry disease ,, Contains global market forecasts ...
Breaking Medicine Technology:Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 2Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 3Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 4Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 5Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 6Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 7Reportlinker Adds Global Markets for Asthma and COPD Drugs 2Reportlinker Adds Global Markets for Asthma and COPD Drugs 3Reportlinker Adds Global Markets for Asthma and COPD Drugs 4Reportlinker Adds Global Markets for Asthma and COPD Drugs 5Reportlinker Adds Global Markets for Asthma and COPD Drugs 6Reportlinker Adds Global Markets for Asthma and COPD Drugs 7Reportlinker Adds Global Markets for Asthma and COPD Drugs 8Reportlinker Adds Global Markets for Asthma and COPD Drugs 9Reportlinker Adds Global Markets for Asthma and COPD Drugs 10Reportlinker Adds Global Markets for Asthma and COPD Drugs 11UC Davis researchers visualize formation of a new synapse 8885 1UC Davis researchers visualize formation of a new synapse 8885 2Group Health Cooperative Shows Investing in More Primary Care Pays for Itself 49287 1Group Health Cooperative Shows Investing in More Primary Care Pays for Itself 49287 2Group Health Cooperative Shows Investing in More Primary Care Pays for Itself 49287 3The power of prayer 3F 49285 1The power of prayer 3F 49285 2
..., Inc. today,announced that it has initiated a Pha...enance therapy in reducing the incidence of pulmon...tive pulmonary disease,(COPD). MP-376 is the compa...solution., The Phase 2, U.S. multi-center randomi...02) is expected to enroll approximately 300,COPD p...
...resented at AASLD annual meeting, Pivotal Phase I... those,who failed prior treatment, SAN FRANCISCO,... today reported that a planned interim analysis of...stigational oral hepatitis C,protease inhibitor, i...kedly increased sustained virologic response (SVR)...
Other Medicine Technology:Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD 2Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10
SmartLite Derm
Triactive
... latest evolution of Smartepil family by DEKA, a h...tion and transdermic vascular treatments. Thanks t...rtepil II Plus allows for carrying out non-invasiv...nts social life. The system is fitted with a wide ...
KOWA Automated Tonometer KT-500
Medicine Products: